The funds are designed to accelerate research being conducted to fight the coronavirus. 24 projects were selected in the first application round. Two of the 24 projects involve clinical studies on the development of vaccines, whereas eight projects focus on developing therapeutic agents. Twelve initiatives aim at developing diagnostic products, and two projects target infection prevention and control.
Vaccine development and development of therapeutics
The companies Themis Bioscience GmbH, Baxalta Innovations GmbH, Apeiron, AOP Orphan Pharmaceuticals AG, Cyprumed GmbH, Marinomed Biotech AG, Apeptico, Panoptes Pharma GesmbH and AIT Angewandte Informationstechnik operate in the field of "vaccine development".
Development of diagnostic products
The following firms focus on the "development of diagnostic products": Qualizyme Diagnostics, Attoquant Diagnostics GmbH, Viravaxx AG, Dr. Gernot Walder GmbH, Genspeed Biotech GmbH, Labdia Labordiagnostik, Lexogen GmbH, Next Generation Sequencing (NGS), Novogenia GmbH, Pharmgenetix GmbH, BioTreaT GmbH, SteadySense GmbH and RPD Rapid Product Development GmbH.
Find more details on the project (in German).
Read more about the current support for your company in times of Corona.